Cargando…
Can We “Hedge” against the Development of Antiviral Resistance among Pandemic Influenza Viruses?
David K. Shay and Benjamin Ridenhour discuss a modeling study predicting that stockpiling a secondary antiviral for use early in a flu pandemic can forestall resistance to the primary stockpiled drug.
Autores principales: | Shay, David K., Ridenhour, Benjamin J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694987/ https://www.ncbi.nlm.nih.gov/pubmed/19564898 http://dx.doi.org/10.1371/journal.pmed.1000103 |
Ejemplares similares
-
Antiviral Response in Pandemic Influenza Viruses
por: García-Sastre, Adolfo
Publicado: (2006) -
Hedging against Antiviral Resistance during the Next Influenza Pandemic Using Small Stockpiles of an Alternative Chemotherapy
por: Wu, Joseph T., et al.
Publicado: (2009) -
Discovery of Influenza A Virus Sequence Pairs and Their Combinations for Simultaneous Heterosubtypic Targeting that Hedge against Antiviral Resistance
por: Wee, Keng Boon, et al.
Publicado: (2016) -
Can We Hedge an Investment Against A Potential Unexpected Environmental Disaster?
por: Halkos, George, et al.
Publicado: (2021) -
Immunizing the Immune: Can We Overcome Influenza’s Most Formidable Challenge?
por: Ellebedy, Ali H.
Publicado: (2018)